ПРЕПРИНТ
О результатах, изложенных в препринтах, не следует сообщать в СМИ как о проверенной информации.
Применение ингибиторов иммунных контрольных точек (ИКТИ) и ингибиторов рецепторов фактора роста эндотелия сосудов (vascular endothelial growth factor, VEGF) значительно улучшило результаты лечения широкого спектра злокачественных новообразований. Однако расширение показаний к применению данных классов лекарственных средств сопровождается формированием нового спектра нежелательных явлений. Среди них особую клиническую значимость приобретает кардиотоксичность, представляющая собой потенциальную угрозу для жизни пациента. Внедрение иммуно- и анти-VEGF терапии в онкологическую практику обусловливает потребность в получении детальных данных о частоте и спектре индуцируемых ими кардиотоксических эффектов. В статью включены опубликованные с 2021 по 2025 годы в сети интернет медицинские исследования и метаанализы, использовались базы данных PubMed, ScienceDirect, Google Scholar, CENTRAL, РИНЦ, в которых просмотрено 545 источников литературы, описывающих частоту развития и гетерогенность кардиоваскулярных нежелательных явлений, ассоциированных с различными схемами применения иммуно- и анти-VEGF терапии.
Зайнетдинова Д. З. 2026. Кардиоваскулотоксичность противоопухолевой терапии ингибиторами иммунных контрольных точек и ингибиторами рецепторов фактора роста эндотелия сосудов: современные представления. PREPRINTS.RU. https://doi.org/10.24108/preprints-3115653
1. Vasyuk Yu.A., Roitberg G.E., Belenkov Yu.N., Oynotkinova O.Sh., Gendlin G.E., Matskeplishvili S.T. et al. Interdisciplinary consensus of the expert council. Cardiovascular toxicity in cancer patients due to chemotherapy and radiation therapy in modern clinical practice (part 1). Proffesors’ Journal. Series: Medical Sciences. 2024;1-2:59-82. [Russian: Васюк Ю.А., Ройтберг Г.Е., Беленков Ю.Н., Ойноткинова О.Ш., Гендлин Г.Е., Мацкеплишвили С.Т. и др. Междисциплинарный Консенсус Совета экспертов. Сердечно-сосудистая токсичность у онкологических больных вследствие химио- и лучевой терапии в современной клинической практике (Часть 1). Профессорский журнал. Серия: медицинские науки. 2024;1-2:59-82.]. DOI: 10.18572/2658-7130-2024-1-2-59-82
2. Zamorano JL, Lancellotti P, Rodriguez Muñoz D, Aboyans V, Asteggiano R, Galderisi M et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines. Eur Heart J.2016;37(36):2768–2801. DOI: 10.1093/eurheartj/ehw211
3. Keramida K, Kyriakou TC, Antoniades A, Tocchetti CG. Immunotherapy-associated Cardiotoxicity: a Comprehensive Review of Checkpoint inhibitors, monoclonal, cellular, and cytokine-based Treatments. Curr Treat Options Oncol. 2025;26(12):1047-1060. DOI: 10.1007/s11864-025-01363-z
4. Kirichenko Yu.Yu., Kulagina T.Yu., Zhigulina O.A., Ilgisonis I.S., Belenkov Yu.N. Cardiac dysfunction and arterial hypertension as manifestations of cardiovasculotoxicity of IVEGF-containing chemotherapy. Clinical case. Kardiologiia. 2024;64(5):33-38. [Russian: Кириченко Ю.Ю., Кулагина Т.Ю., Жигулина О.А., Ильгисонис И.С., Беленков Ю.Н. Дисфункция миокарда и артериальная гипертензия как проявления кардиоваскулотоксичности химиотерапии с включением IVEGF: клиническое наблюдение. Кардиология. 2024;64(5):33-38]. DOI: 10.18087/cardio.2024.5.n2661
5. Khidirova L.D., Latsvieva A.E., Vederin A.V. Cardiotoxicity mechanisms of antitumor therapy with immune checkpoint inhibitors: new achievements. Rational Pharmacotherapy in Cardiology. 2024;20(2):265-274. [Russian: Хидирова Л.Д., Лацвиева А.Е., Ведерин А.А. Механизмы кардиотоксичности противоопухолевой терапии ингибиторами иммунных контрольных точек: современные достижения. Рациональная фармакотерапия в кардиологии. 2024;20(2):265-274]. DOI: 10.20996/1819-6446-2024-3022
6. Buziashvili Yu.I., Matskeplishvili S.T., Asymbekova E.U., Akhmedov D.R., Akildzhonov F.R. Current understanding of the mechanisms of cardiotoxicity associated with immunotherapy. Creative Cardiology. 2024;18(4): 81–391. [Russian: Бузиашвили Ю.И., Мацкеплишвили С.Т., Асымбекова Э.У., Ахмедов Д.Р., Акилджонов Ф.Р. Современные представления о механизмах кардиотоксичности, ассоциированной с иммунотерапией. Креативная кардиология. 2024;18(4):381-391]. DOI: 10.24022/1997-3187-2024-18-4-381-391
7. Buziashvili J.I., Asymbekova E.U., Tugeeva E.F., Artamonova E.V., Akildzhonov F.R. Cardiotoxicity of checkpoint inhibitors: focus on immune side effects. Medical alphabet. 2024;(7):26-33. [Russian: Бузиашвили Ю.И., Асымбекова Э.У., Тугеева Э.Ф., Артамонова Е.В., Акилджонов Ф.Р. Кардиотоксичность ингибиторов контрольных точек: фокус на иммунных побочных эффектах. Медицинский алфавит. 2024;(7):26-33]. DOI: 10.33667/2078-5631-2024-7-26-33
8. Cagnazzo R, Stabile M, Zoppoli G, De Boer RA, Meijers WC, van Der Meer P et al. Mismatch Between Preclinical Cardio-Oncology and Clinical Oncology Research. JACC CardioOncol. 2025;7(6):770-773. DOI: 10.1016/j.jaccao.2025.05.012
9. ElTanbouly MA, Noelle RJ. Rethinking peripheral T cell tolerance: checkpoints across a T cell's journey. Nat Rev Immunol. 2021;21(4):257-267. DOI: 10.1038/s41577-020-00454-2
10. Alemohammad H, Najafzadeh B, Asadzadeh Z, Baghbanzadeh A, Ghorbaninezhad F, Najafzadeh A et al. The importance of immune checkpoints in immune monitoring: A future paradigm shift in the treatment of cancer. Biomed Pharmacother. 2022;146:112516. DOI: 10.1016/j.biopha.2021.112516
11. Kalaora S., Nagler A., Wargo J.A., Samuels Y. Mechanisms of immune activation and regulation: lessons from melanoma. Nat Rev Cancer. 2022;22:195–207. DOI: 10.1038/s41568-022-00442-9
12. Pardoll D.M. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12:252-264. DOI: 10.1038/nrc3239
13. Pătru IR, Anghel AV, Galeschi ER, Bătăuș LC, Ionescu AI, Negru AG et al. The Impact of Immune-Related Adverse Events on the Survival of Patients Treated with Immune Checkpoint Inhibitors: The Distinct Role of Cardiac Toxicities. J Clin Med. 2025;14(21):7794. DOI: 10.3390/jcm14217794
14. Sayour NV, Kucsera D, Alhaddad AR, Tóth VÉ, Gergely TG, Kovács T et al. Effects of sex and obesity on immune checkpoint inhibition-related cardiac systolic dysfunction in aged mice. Basic Res Cardiol. 2025;120(1):207-223. DOI: 10.1007/s00395-024-01088-4
15. Alturki NA. Review of the Immune Checkpoint Inhibitors in the Context of Cancer Treatment. J Clin Med. 2023;12(13):4301. DOI: 10.3390/jcm12134301
16. Becker RC. Immune checkpoint inhibitors and cardiovascular toxicity: immunology, pathophysiology, diagnosis, and management. J Thromb Thrombolysis. 2025;58(8):1021-1044. DOI: 10.1007/s11239-025-03146-7
17. Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med 2018;378(2):158-168. DOI: 10.1056/NEJMra1703481
18. Stefanou E, Tsitsinakis G, Karageorgou D, Kole C. Immunotherapy-Associated Cardiotoxicity: Current Insights and Future Directions for Precision Cardio-Oncology. Cancers (Basel). 2025;17(17):2838. DOI: 10.3390/cancers17172838
19. Kushnareva E.A., Gavriluk N.D., Shuginova T.N., Urumova E.L., Karelkina E.V., Simakova M.A., et al. Immune checkpoint inhibitors related cardiovascular toxicity: 3‑mounth follow-up. Kardiologiia. 2023;63(7):23–31. [Russian: Кушнарева Е.А., Гаврилюк Н.Д., Шугинова Т.Н., Урумова Е.Л., Карелкина Е.В., Симакова М.А., и др. Сердечно-сосудистые осложнения при иммунной противоопухолевой терапии ингибиторами контрольных точек: результаты 3‑месячного наблюдения. Кардиология. 2023;63(7):23-31]. DOI: 10.18087/cardio.2023.7.n2394
20. Li C., Bhatti S.A., Ying J. Immune Checkpoint Inhibitors-Associated Cardiotoxicity. Cancers. 2022;14:1145. DOI: 10.3390/cancers14051145
21. Kong Y, Wang X, Qie R. Immunotherapy-associated cardiovascular toxicities: Insights from preclinical and clinical studies. Front. Oncol. 2024;14:1347140. DOI: 10.3389/fonc.2024.1347140
22. Lipshultz SE, Adams MJ, Colan SD, Constine LS, Herman EH, Hsu DT et al. Long-term cardiovascular toxicity in children, adolescents, and young adults who receive cancer therapy: pathophysiology, course, monitoring, management, prevention, and research directions: a scientific statement from the American heart association. Circulation. 2013;128(17):1927-95. DOI: 10.1161/CIR.0b013e3182a88099
23. Gergely TG, Drobni ZD, Sayour NV, Ferdinandy P, Varga ZV. Molecular fingerprints of cardiovascular toxicities of immune checkpoint inhibitors. Basic Res Cardiol. 2025;120(1):187-205. DOI: 10.1007/s00395-024-01068-8
24. Balluzek M.F., Protsenko S.A., Potievskaya V.I. Myocarditisassociated with immune checkpoint inhibitor therapies: diagnostic and treatment strategies. Voprosy Onkologii. 2023;69(2):219-226. [Russian: Баллюзек М.Ф., Проценко С.А., Потиевская В.И. Миокардиты, ассоциированные с терапией ингибиторами иммунных контрольных точек: стратегии диагностики и лечения. Вопросы онкологии. 2023;69(2):219-226]. DOI: 10.37469/0507-3758-2023-69-2-219-226
25. Mahmood SS, Fradley MG, Cohen JV, Nohria A, Reynolds KL, Heinzerling LM et al. Myocarditis in Patients Treated with Immune Checkpoint Inhibitors. J. Am. Coll. Cardiol. 2018;71:1755–1764. DOI: 10.1016/j.jacc.2018.02.037
26. Papanikolopoulou A, Michalopoulou H, Kyriakoulis KG, Alexiou P, Syrigos N, Vathiotis J et al. Cardiovascular Toxicity Associated With Immune Checkpoint Inhibitors: Interpreting the Discrepancy Between Clinical Trials and Real-World Data. Cureus. 2025;17(6):e87049. DOI: 10.7759/cureus.87049
27. Andres MS, Llamedo MC, Ramalingam S, Lyon AR. Immunotherapy and the heart: understanding the cardiovascular risks of immune checkpoint inhibitors. Presse Med. 2025;104327. DOI: 10.1016/j.lpm.2025.104327
28. Suero-Abreu GA, Zanni MV, Neilan TG. Atherosclerosis with immune checkpoint inhibitor therapy: evidence, diagnosis, and management: JACC: cardiooncology state-of-the-art review. JACC CardioOncol. 2022;4(5):598–615. DOI: 10.1016/j.jaccao.2022.11.011
29. Amiri-Kordestani L, Moslehi J, Cheng J, Tang S, Schroeder R, Sridhara R et al. Cardiovascular adverse events in immune checkpoint inhibitor clinical trials: a U.S. Food and drug administration pooled analysis. J Clin Oncol. 2018;36(15_suppl):3009. DOI: 10.1200/JCO.2018.36.15_suppl.3009
30. Oren O, Yang EH, Molina JR, Bailey KR, Blumenthal RS, Kopecky SL. Cardiovascular health and outcomes in cancer patients receiving immune checkpoint inhibitors. Am J Cardiol. 2020;125(12):1920–1926. DOI: 10.1016/j.amjcard.2020.02.016
31. Drobni ZD, Alvi RM, Taron J, Zafar A, Murphy SP, Rambarat PK et al. Association between immune checkpoint inhibitors with cardiovascular events and atherosclerotic plaque. Circulation. 2020;142(24):2299-2311. DOI: 10.1161/CIRCULATIONAHA.120.049981
32. Lyon AR, Yousaf N, Battisti NML., Moslehi J, Larkin J. Immune checkpoint inhibitors and cardiovascular toxicity. Lancet Oncol. 2018;19:e447–e458. DOI: 10.1016/S1470-2045(18)30457-1
33. He Y, Yu H, Dai S, He M, Ma L, Xu Z et al. Immune checkpoint inhibitors break whose heart? Perspectives from cardio-immuno-oncology. Genes Dis. 2023;11(2):807-818. DOI: 10.1016/j.gendis.2023.01.024
34. Gamero MT, Patel A, Storozynsky E. The Good (Tumor Killing) and the Bad (Cardiovascular Complications) of Immunologic Checkpoint Inhibitors. Curr Cardiol Rep. 2024;26(12):1487-1498. DOI: 10.1007/s11886-024-02147-x
35. Zhang X, Gan Y, Zhu H, Liu Z, Yao X, Cheng C et al. Role of mitochondrial metabolism in immune checkpoint inhibitors-related myocarditis. Front. Cardiovasc. Med. 2023;10:1112222. DOI: 10.3389/fcvm.2023.1112222
36. Luo L, Liu Y, Lu J, Zhang Y, Fan G, Tang X et al. Risk factors for cardiovascular adverse events from immune checkpoint inhibitors. Front. Oncol. 2023;13:1104888. DOI: 10.3389/fonc.2023.1104888
37. Yousif LI, Screever EM, Versluis D, Aboumsallem JP, Nierkens S, Manintveld OC et al. Risk factors for immune checkpoint inhibitor-mediated cardiovascular toxicities. Curr. Oncol. Rep. 2023;25:753-763. DOI: 10.1007/s11912-023-01414-4
38. Hasan S, Dinh K, Lombardo F, Kark J. Doxorubicin cardiotoxicity in African Americans. J. Natl. Med. Assoc. 2004;96:196–199. PMID: 14977278. PMCID: PMC2594938
39. Salem J-E, Manouchehri A, Moey M, Lebrun-Vignes B, Bastarache L, Pariente A et al. Cardiovascular toxicities associated with immune checkpoint inhibitors: An observational, retrospective, pharmacovigilance study. Lancet Oncol. 2018;19:1579-1589. DOI: 10.1016/S1470-2045(18)30608-9
40. Vasyuk Yu.A., Roitberg G.E., Belenkov Yu.N., Oynotkinova O.Sh., Gendlin G.E., Matskeplishvili S.T. et al. Interdisciplinary Consensus of the Expert Council. Cardiovascular toxicity in cancer patients due to chemotherapy and radiation therapy in modern clinical practice (part 2). Proffesors’ Journal. Series: Medical Sciences. 2024;3-4:25-51. [Russian: Васюк Ю.А., Ройтберг Г.Е., Беленков Ю.Н., Ойноткинова О.Ш., Гендлин Г.Е., Мацкеплишвили С.Т. и др. Междисциплинарный консенсус совета экспертов. Сердечно-сосудистая токсичность у онкологических больных вследствие химио- и лучевой терапии в современной клинической практике (часть 2). Профессорский журнал. Серия: Медицинские науки. 2024;3-4:25-51]. DOI: 10.18572/2658-7130-2024-3-4-25-51
41. Rankin S, Elyan B, Jones R, Venugopal B, Mark PB, Lees JS et al. Cardiovascular Eligibility Criteria and Adverse Event Reporting in Combined Immune Checkpoint and VEGF Inhibitor Trials. JACC CardioOncol. 2024;6(2):267-279. DOI: 10.1016/j.jaccao.2023.12.010
42. Touyz RM, Lang NN, Herrmann J, van den Meiracker AH, Danser AHJ. Recent advances in hypertension and cardiovascular toxicities with vascular endothelial growth factor inhibition. Hypertension. 2017;70:220-226. DOI: 10.1161/HYPERTENSIONAHA.117.08856
43. Dobbin SJH, Cameron AC, Petrie MC, Jones RJ, Touyz RM, Lang NN. Toxicity of cancer therapy: What the cardiologist needs to know about angiogenesis inhibitors. Heart. 2018;104:1995–2002. DOI: 10.1136/heartjnl-2018-313726
44. Efentakis P, Andreadou I, Iliodromitis KE, Triposkiadis F, Ferdinandy P, Schulz R et al. Myocardial Protection and Current Cancer Therapy: Two Opposite Targets with Inevitable Cost. Int J Mol Sci. 2022;23(22):14121. DOI: 10.3390/ijms232214121
45. Vallerio P, Orenti A, Tosi F, Maistrello M, Palazzini M, Cingarlini S et al. Major adverse cardiovascular events associated with VEGF-targeted anticancer tyrosine kinase inhibitors: a real-life study and proposed algorithm for proactive management. ESMO Open. 2022;7(1):100338. DOI: 10.1016/j.esmoop.2021.100338
46. Mihalcea D, Memis H, Mihaila S, Vinereanu D. Cardiovascular Toxicity Induced by Vascular Endothelial Growth Factor Inhibitors. Life (Basel). 2023;13(2):366. DOI: 10.3390/life13020366
47. Travers RJ, Stepanian A, Jaffe IZ. Endothelium as a Source of Cardiovascular Toxicity From Antitumor Kinase Inhibitors. Arterioscler Thromb Vasc Biol. 2024;44(10):2143-2153. DOI: 10.1161/ATVBAHA.124.319864
48. Stachyra-Strawa P, Szatkowska-Sieczek L, Cisek P, Gołębiowski P, Grzybowska-Szatkowska L. Cardiac and nephrological complications related to the use of antiangiogenic and anti-programmed cell death protein 1 receptor/programmed cell death protein 1 ligand therapy. Genes (Basel). 2024;15(2):177. DOI: 10.3390/genes15020177
49. Ciccarese C, Anghelone A, Stefani A, Cigliola A, Strusi A, D'Agostino F et al. The incidence and relative risk of major adverse cardiovascular events and hypertension in patients treated with immune checkpoint inhibitors plus tyrosine-kinase inhibitors for solid tumors: a systemic review and meta-analysis. Expert Rev Anticancer Ther. 2024;24(7):623-633. DOI: 10.1080/14737140.2024.2357814
50. Chen YC, Huang CY, Lien LM, Chen JH, Hsieh FI. Cardiovascular toxicity of angiogenesis inhibitors among patients with cancer in Taiwan: a nested case-control study. J Am Heart Assoc. 2024;13(1):e030263. DOI: 10.1161/JAHA.123.030263
51. Sultan S, Acharya Y, Donnellan P, Hynes N, Kerin M, Soliman O. Acute aortic catastrophe caused by cardiovascular oncological manipulation by tyrosine kinase inhibitors with immune checkpoint blockades: a case report and literature review. Eur Heart J Case Rep. 2024;8(4):ytae169. DOI: 10.1093/ehjcr/ytae169
52. Franczyk B, Rysz J, Ławiński J, Ciałkowska-Rysz A, Gluba-Brzózka A. Cardiotoxicity of selected vascular endothelial growth factor receptor tyrosine kinase inhibitors in patients with renal cell carcinoma. Biomedicines. 2023;11(1):181. DOI: 10.3390/biomedicines11010181
53. Kuang H, Yan Q, Li Z, Lin A, Li K, Zhang J et al. Comprehensive analysis of VEGF/VEGFR inhibitor-induced immune-mediated hypertension: integrating pharmacovigilance, clinical data, and preclinical models. Front Immunol. 2024;15:1488853. DOI: 10.3389/fimmu.2024.1488853
54. Izquierdo-Condoy JS, Arias-Intriago M, Becerra Cardona DA, García-Cañarte S, Vinueza-Moreano P. Anticancer chemotherapy-induced atherosclerotic cardiovascular disease: a comprehensive review. Life (Basel). 2025;15(2):245. DOI: 10.3390/life15020245
55. Lessomo FYN, Mandizadza OO, Mukuka C, Wang ZQ. A comprehensive review on immune checkpoint inhibitors induced cardiotoxicity characteristics and associated factors. Eur J Med Res. 2023;28(1):495. DOI: 10.1186/s40001-023-01464-1
56. Wang Y., Cui C., Deng L., Wang L., Ren X. Cardiovascular toxicity profiles of immune checkpoint inhibitors with or without angiogenesis inhibitors: a real-world pharmacovigilance analysis based on the FAERS database from 2014 to 2022. Front Immunol. 2023;14:1127128. DOI: 10.3389/fimmu.2023.1127128
57. Crocetto F, Ferro M, Buonerba C. et al. Comparing cardiovascular adverse events in cancer patients: a meta-analysis of combination therapy with angiogenesis inhibitors and immune checkpoint inhibitors versus angiogenesis inhibitors alone. Crit Rev Oncol Hematol. 2023;188:104059. DOI: 10.1016/j.critrevonc.2023.10405
58. Ishikawa Y, Suzuki M, Konda E, Hashimura H, Ikeda Y, Osue T et al. Left ventricular dysfunction caused by combined pembrolizumab and lenvatinib following doxorubicin: which agent is the culprit? JACC Case Rep. 2025;30(26):104907. DOI: 10.1016/j.jaccas.2025.104907
59. Beavers CJ, Rodgers JE, Bagnola AJ, Beckie TM, Campia U, Di Palo KE et al. Cardio-oncology drug interactions: a scientific statement from the American heart association. Circulation. 2022:145(15):e811–e838. DOI: 10.1161/CIR.0000000000001056
60. Lyon AR, López-Fernández T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J Cardiovasc Imaging. 2022;23(10):e333-e465. DOI: 10.1093/ehjci/jeac106
61. Aura C, Salcedo L, Loayza Pintado J, Matos C, Mogollon I, Arias F et al. Silent damage, early signals: A narrative review of the evolving role of cardiac biomarkers in oncology-driven cardiotoxicity. J Investig Med. 2025;14:10815589251382263. DOI: 10.1177/10815589251382263
62. Belenkov Yu.N., Ilgisonis I.S., Khabarova N.V., Kirichenko Yu.Yu. Modern Instrumental Methods of Diagnostics and Risk Assessment of Developing Antitumor Therapy Cardiovasculotoxicity. Kardiologiia. 2024;64(8):3-12. [Russian: Беленков Ю.Н., Ильгисонис И.С., Хабарова Н.В., Кириченко Ю.Ю. Современные инструментальные методы диагностики и оценки риска развития кардиоваскулотоксичности противоопухолевой терапии. Кардиология. 2024;64(8):3-12]. DOI: 10.18087/cardio.2024.8.n2753
63. Stone JR, Kanneganti R, Abbasi M, Akhtari M. Monitoring for chemotherapy-related cardiotoxicity in the form of left ventricular systolic dysfunction: a review of current recommendations. JCO Oncol Pract. 2021;17(5):228-236. DOI: 10.1200/OP.20.00924
64. Xiao H, Wang X, Li S, Liu Y, Cui Y, Deng X. Advances in biomarkers for detecting early cancer treatment-related cardiac dysfunction. Front Cardiovasc Med. 2021;8:753313. DOI: 10.3389/fcvm.2021.753313
65. Ananthan K, Lyon AR. The role of biomarkers in cardio-oncology. J Cardiovasc Transl Res. 2020;13(3):431-450. DOI: 10.1007/s12265-020-10042-3
66. Thavendiranathan P, Wintersperger BJ, Flamm SD, Marwick ThH. Cardiac MRI in the assessment of cardiac injury and toxicity from cancer chemotherapy: a systematic review. Circ Cardiovasc Imaging. 2013;6(6):1080-91. DOI: 10.1161/CIRCIMAGING.113.000899
67. Patnaik JL, Byers T, DiGuiseppi C, Dabelea D, Denberg ThD. Cardiovascular disease competes with breast cancer as the leading cause of death for older females diagnosed with breast cancer: a retrospective cohort study. Breast Cancer Res. 2011;13(3):R64. DOI: 10.1186/bcr2901
68. Celebi Coskun E, Coskun A, Sahin AB, Levent F, Coban E, Koca F et al. Left ventricular global longitudinal strain in patients treated with immune checkpoint inhibitors. Front Oncol. 2024;14:1453721. DOI: 10.3389/fonc.2024.1453721
69. Trimarchi G, Carerj S, Di Bella G, Manganaro R, Pizzino F, Restelli D, et al. Clinical Applications of Myocardial Work in Echocardiography: A Comprehensive Review. J Cardiovasc Echogr. 2024;34(3):99-113. DOI: 10.4103/jcecho.jcecho_37_24
70. Tamura Y, Tamura Y. Usefulness of Longitudinal Strain to Assess Cancer Therapy-Related Cardiac Dysfunction and Immune Checkpoint Inhibitor-Induced Myocarditis. Pharmaceuticals (Basel). 2023;16(9):1297. DOI: 10.3390/ph16091297
71. Xu A, Yuan M, Zhan X, Zhao G, Mu G, Wang T et al. Early detection of immune checkpoint inhibitor-related subclinical cardiotoxicity: A pilot study by using speckle tracking imaging and three-dimensional echocardiography. Front Cardiovasc Med. 2022;9:1087287. DOI: 10.3389/fcvm.2022.1087287
72. Egberts BK, Ananthakrishna R, Perry R, Woodman RJ, Sutton A, Pasupathy S et al. Myocardial Injury Following Immune Checkpoint Inhibitors: An Australian Experience. Heart Lung Circ. 2025;34(6):596-605. DOI: 10.1016/j.hlc.2024.11.018
73. Sonaglioni A, Bruno A, Nicolosi GL, Fossile E, Rubuano C, Ricotta R et al. Effect of immune checkpoint inhibitor therapy on biventricular mechanics in cancer patients over a short-term follow-up: a systematic review. Front Immunol. 2025;16:1576175. DOI: 10.3389/fimmu.2025.1576175
74. Delombaerde D, Vulsteke C, Van de Veire N, Vervloet D, Moerman V, Van Calster L et al. Close cardiovascular monitoring during the early stages of treatment for patients receiving immune checkpoint inhibitors. Pharmaceuticals (Basel). 2024;17(7):965. DOI: 10.3390/ph17070965
75. Leong DP, Waliany S, Abdel-Qadir H, Atkins KM, Neilan TG, Lang NN et al. Cardiovascular considerations during cancer therapy: gaps in evidence and JACC: cardiooncology expert panel recommendations. JACC CardioOncol. 2024;6(6):815-834. DOI: 10.1016/j.jaccao.2024.06.005
76. Argulian E, Narula J. Myocardial work in cardio-oncology: how well does it work? JACC Cardiovasc Imaging. 2022;15(8):1377-1379. DOI: 10.1016/j.jcmg.2022.03.021
77. Vaz Ferreira V, Mano TB, Cardoso I, Coutinho Cruz M, Moura Branco L, Almeida-Morais L et al. Myocardial work brings new insights into left ventricular remodelling in cardio-oncology patients. Int J Environ Res Public Health. 2022;19(5):2826. DOI: 10.3390/ijerph19052826
78. Li X, Wang C, Kang R, Zhao Y, Chen L, Liu F et al. Evaluating the effect of PD-1 inhibitors on left ventricular function in lung cancer with noninvasive myocardial work. Quant Imaging Med Surg. 2023;13(5):3241-3254. DOI: 10.21037/qims-22-817
79. Guan J, Bao W, Xu Y, Yang W, Li M, Xu M, et al. Assessment of myocardial work in cancer therapy-related cardiac dysfunction and analysis of CTRCD prediction by echocardiography. Front Pharmacol. 2021;12:770580. DOI: 10.3389/fphar.2021.770580
80. Liu G, Liu Z, Lang M. Echocardiography myocardial work assessment of chemotherapy-induced cardiotoxicity: a systematic review and meta-analysis. Med Ultrason. 2025;27(4):483-493. DOI: 10.11152/mu-4502
81. Pohl J, Mincu RI, Mrotzek SM, Hinrichs L, Michel L, Livingstone E et al. ECG changes in melanoma patients undergoing cancer therapy-data from the ECoR registry. J Clin Med. 2020;9(7):2060. DOI: 10.3390/jcm9072060
82. Oksen D, Gecit MH, Arslan S, Aslan M, Yavuz YE, Secmeler S et al. Detecting subclinical cardiotoxicity during immune checkpoint inhibitor therapy: a combined GLS and ECG repolarization analysis. Front Oncol. 2025;15:1615209. DOI: 10.3389/fonc.2025.1615209
83. Coskun A, Celebi Coskun E, Bilgehan Sahin A, Levent F, Coban E, Koca F et al. Prediction of cardiac arrhythmias in cancer patients treated with immune checkpoint inhibitors using electrocardiogram. Diagnostics (Basel). 2025;15(10):1235. DOI: 10.3390/diagnostics15101235
84. Shakaryants G.A., Budanova D.A., Lobastov K.V., Khabarova N.V., Kirichenko Yu.Yu., Belenkov Yu.N. Treatment and secondary prevention of venous thromboembolism in cancer patients. Kardiologiia. 2020;60(3):71-79. [Russian: Шакарьянц Г.А., Буданова Д.А., Лобастов К.В., Хабарова Н.В., Кириченко Ю.Ю., Беленков Ю.Н. Лечение и вторичная профилактика венозных тромбоэмболических осложнений у онкологических больных. Кардиология. 2020;60(3):71-79]. DOI: 10.18087/cardio.2020.3.n904
85. Boire A, Burke K, Cox TR, Guise T, Jamal-Hanjani M, Janowitz T et al. Why do patients with cancer die? Nat. Rev. Cancer. 2024;24:578–589. DOI: 10.1038/s41568-024-00708-4
86. Liu G, Chen T, Zhang X, Hu B, Shi H. Immune checkpoint inhibitor-associated cardiovascular toxicities: A review. Heliyon. 2024;10(5):e25747. DOI: 10.1016/j.heliyon.2024.e25747
87. Fowler C, Pastores SM. Venous thromboembolic events in cancer immunotherapy: a narrative review. J Clin Med. 2025;14(14):4926. DOI: 10.3390/jcm14144926
88. Moik F, Chan WSE, Wiedemann S, Hoeller C, Tuchmann F, Aretin MB et al. Incidence, risk factors, and outcomes of venous and arterial thromboembolism in immune checkpoint inhibitor therapy. Blood. 2021;137(12):1669–78. DOI: 10.1182/blood.2020007878
89. Wang TF, Khorana AA, Carrier M. Thrombotic complications associated with immune checkpoint inhibitors. Cancers (Basel). 2021;13(18):4606. DOI: 10.3390/cancers13184606
90. Alghamdi EA, Aljohani H, Alghamdi W, Alharbi F. Immune checkpoint inhibitors and potential risk of thromboembolic events: Analysis of the WHO global database of individual case safety reports. Saudi Pharm J. 2022 Aug;30(8):1193-1199. DOI: 10.1016/j.jsps.2022.06.010
91. Van Lent A, Puscasu R, Kaasjager KAH, Haitjema S, Suelmann BBM, Verhaar MC et al. Venous and arterial thrombosis in patients receiving immune checkpoint inhibitors. PLoS One. 2025;20(4):e0321112. DOI: 10.1371/journal.pone.0321112
92. Goel A, Khorana A, Kartika T, Gowda S, Tao DL, Thawani R et al. Assessing the risk of thromboembolism in cancer patients receiving immunotherapy. Eur J Haematol. 2022;108(4):271-277. DOI: 10.1111/ejh.13734
93. Niimura T, Goda M, Miyata K, Matsumoto J, Yoshioka T, Hamano H, et al. Evaluation of cardiovascular toxicity of the atezolizumab and bevacizumab combination. Front Drug Saf Regul. 2023;3:1213771. DOI: 10.3389/fdsfr.2023.1213771
94. Wells PS, Anderson DR, Bormanis J, F Guy, M Mitchell, L Gray et al. Value of assessment of pretest probability of deep-vein thrombosis in clinical management. Lancet 1997;350(9094):1795–1798. DOI: 10.1016/S0140-6736(97)08140-3
95. van Belle A, Büller HR, Huisman MV, Huisman PM, Kaasjager K, Kamphuisen PW et al. Effectiveness of managing suspected pulmonary embolism using an algorithm combining clinical probability, D-dimer testing, and computed tomography. JAMA 2006;295(2):172–179. DOI: 10.1001/jama.295.2.172
96. Shlyk I.F. Informativeness of the thrombodynamic method in assessing the state of hemostasis in patients with coronary heart disease. Medical Herald of the South of Russia. 2019;10(2):48-54. [Russian: Шлык И.Ф. Информативность метода тромбодинамики в оценке состояния гемостаза у пациентов с ишемической болезнью сердца. Медицинский вестник Юга России. 2019;10(2):48-54]. DOI: 10.21886/2219-8075-2019-10-2-48-54
97. Vasilenko I, Vlasova E, Metelin V, Balkanov A, Bichenkov O. PO-22 - Thrombodynamics test for analysis of hemostasis in patients with malignant tumors and predicting thrombotic complications. Thromb Res. 2016;140(1):S184. DOI: 10.1016/S0049-3848(16)30155-4
98. Fawaz H, Numan H, El Charif MH, Charbel N, El Khoury S, Rizkallah J et al. Exploring the emerging association between immune checkpoint inhibitors and thrombosis. J Clin Med. 2025;14(10):3451. DOI: 10.3390/jcm14103451
